Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action
出版年份 2023 全文链接
标题
Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action
作者
关键词
-
出版物
BIOCHEMICAL PHARMACOLOGY
Volume -, Issue -, Pages 115443
出版商
Elsevier BV
发表日期
2023-01-30
DOI
10.1016/j.bcp.2023.115443
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Mechanisms of gefitinib-induced QT prolongation
- (2021) Ling-Jun Jie et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review
- (2021) Mohammad Farris Iman Leong Bin Abdullah et al. Frontiers in Pharmacology
- ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1
- (2020) Grzegorz S Nowakowski et al. Future Oncology
- Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs
- (2020) Agapios Sachinidis Cells
- Revisiting the hERG safety margin after 20 years of routine hERG screening
- (2020) Derek J. Leishman et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
- (2020) Nathalie Percie du Sert et al. PLOS BIOLOGY
- Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective
- (2020) Hugo M. Vargas et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Myocardial Dysfunction after Severe Food Restriction Is Linked to Changes in the Calcium-Handling Properties in Rats
- (2019) Adriana Fernandes de Deus et al. Nutrients
- Mechanical stretch increases L-type calcium channel stability in cardiomyocytes through a polycystin-1/AKT-dependent mechanism
- (2018) A. Córdova-Casanova et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- The cardiac ryanodine receptor, but not sarcoplasmic reticulum Ca2+-ATPase, is a major determinant of Ca2+ alternans in intact mouse hearts
- (2018) Bo Sun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
- (2016) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- SKF-96365 blocks human ether-à-go-go-related gene potassium channels stably expressed in HEK 293 cells
- (2016) Hui Liu et al. PHARMACOLOGICAL RESEARCH
- A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma
- (2016) Xueying Li et al. Oncotarget
- The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line
- (2015) Kazumi Hagiwara et al. APOPTOSIS
- Effects of enzastaurin and its metabolites on the QT interval in cancer patients
- (2015) Pamela A. Welch et al. JOURNAL OF CLINICAL PHARMACOLOGY
- QT interval correction assessment in the anesthetized guinea pig
- (2015) Pierre Morissette et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study
- (2014) L. B. Kilburn et al. NEURO-ONCOLOGY
- Mechanisms of Altered Ca 2+ Handling in Heart Failure
- (2013) Min Luo et al. CIRCULATION RESEARCH
- Slow Delayed Rectifier Potassium Current Blockade Contributes Importantly to Drug-Induced Long QT Syndrome
- (2013) Christiaan C. Veerman et al. Circulation-Arrhythmia and Electrophysiology
- A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma
- (2013) Eric Jourdan et al. LEUKEMIA & LYMPHOMA
- Modulation of Pancreatic Tumor Potential by Overexpression of Protein Kinase C β1
- (2013) Stéfano M. Cirigliano et al. PANCREAS
- A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer
- (2012) Bjørn H. Grønberg et al. LUNG CANCER
- Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
- (2011) Christiane Querfeld et al. LEUKEMIA & LYMPHOMA
- A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
- (2011) Teri N. Kreisl et al. NEURO-ONCOLOGY
- Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
- (2011) N. Butowski et al. NEURO-ONCOLOGY
- Role of hERG potassium channel assays in drug development
- (2010) Birgit Priest et al. Channels
- The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation
- (2010) Hui Liu et al. PHARMACOLOGICAL RESEARCH
- Protein Kinase Cβ Is an Effective Target for Chemoprevention of Colon Cancer
- (2009) Alan P. Fields et al. CANCER RESEARCH
- Pharmacologically Induced Long QT Type 2 Can Be Rescued by Activation of IKs With Benzodiazepine R-L3 in Isolated Guinea Pig Cardiomyocytes
- (2009) Jakob Dahl Nissen et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Control of heart rate by cAMP sensitivity of HCN channels
- (2009) J. Alig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
- (2008) C Tekle et al. BRITISH JOURNAL OF CANCER
- Centrosomal PKC II and Pericentrin Are Critical for Human Prostate Cancer Growth and Angiogenesis
- (2008) J. Kim et al. CANCER RESEARCH
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
- (2008) Ming Hui Chen et al. CIRCULATION
- Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C
- (2008) Piotr Jasinski et al. EUROPEAN JOURNAL OF CANCER
- Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells
- (2008) Floriana Morgillo et al. MOLECULAR CANCER THERAPEUTICS
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
- (2007) F. Morschhauser et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More